USA
Analytical Standards
Controlled Research Environment
Research Product
Tesamorelin / CJC-1295 / Ipamorelin
1. Product Overview
Tesamorelin / CJC-1295 / Ipamorelin is a multi-component research peptide blend combining three extensively studied growth hormone regulatory peptides in a standardized lyophilized formulation. The blend has attracted scientific interest in research involving growth hormone signaling pathways, endocrine regulation, metabolic processes, body composition studies, and peptide receptor interactions. Each component is selected for its unique mechanism of interaction within growth hormone-related biological systems.
Manufactured in a controlled research environment, the formulation undergoes analytical testing to verify identity, purity, and consistency prior to release. The product is supplied as a lyophilized research peptide blend intended exclusively for laboratory and scientific research applications.
2. Specifications
| Product Name | Tesamorelin / CJC-1295 / Ipamorelin | Testing Method | HPLC |
|---|---|---|---|
| Synonym | Tesamorelin / CJC-1295 / Ipamorelin | Storage Condition | 2-8C |
| Format | Lyophilized Powder | Shelf Life | 24 Months |
| Content | 12 mg per vial | Manufacturing Standard | GMP Standard Research Environment |
| Purity | >=99% HPLC | Country of Origin | USA |
| Appearance | White to Off White Lyophilized Powder | Intended Use | Research Use Only |
3. Research Summary
Tesamorelin / CJC-1295 / Ipamorelin is a multi-component research peptide blend combining three extensively studied peptides involved in growth hormone regulatory and endocrine signaling pathways. This formulation has attracted scientific interest in studies involving peptide receptor interactions, growth hormone-related biological processes, neuroendocrine signaling, metabolic regulation, and cellular communication mechanisms.
Tesamorelin and CJC-1295 have been investigated for their interaction with growth hormone-releasing hormone (GHRH) pathways, while Ipamorelin has been studied for its interaction with growth hormone secretagogue receptors (GHS-R). Ongoing laboratory research continues to explore the combined biological activity of these peptides in endocrine, metabolic, and peptide signaling models.
4. Scientific References
- Thorner MO, Chapman IM, Gaylinn BD, Pezzoli SS, Hartman ML. Growth hormone-releasing hormone and growth hormone secretagogues in research and clinical investigation. Endocrine Reviews. 1997;18(5):621-645.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone secretion by CJC-1295. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805.
- Jette L, Leger R, Thibaudeau K, et al. Human growth hormone releasing factor analogue (CJC-1295) studies in endocrine research. Growth Hormone & IGF Research. 2005;15(6):367-377.
- Deghenghi R, Cananzi MM, Torsello A, et al. Growth hormone-releasing activity of Ipamorelin. European Journal of Endocrinology. 1998;139(1):89-95.
- Falutz J, Allas S, Blot K, et al. Metabolic and endocrine research involving Tesamorelin. New England Journal of Medicine. 2007;357(23):2359-2370.
Disclaimer: This product is intended strictly for research use only. It is not intended for human consumption, clinical application, diagnostic procedures, therapeutic use, veterinary use, or household use. The information provided is for scientific and educational reference purposes only and should not be interpreted as medical advice, treatment guidance, or usage instructions. This product should be handled only by qualified professionals trained in laboratory practices. Purchasers and end users are solely responsible for ensuring compliance with all applicable laws, regulations, and institutional requirements governing the purchase, storage, handling, and use of research materials.
